Prevention and treatment of benign prostatic hyperplasia using a selective inhibitor of the production of reactive oxygen species of mitochondrial origin
A method of preventing and/or treating disease in which reactive oxygen species (or ROSs) of mitochondrial origin are involved. The method involves use of an inhibitor of mitochondrial ROS production, in particular, of anethole trithione, for the prevention and/or treatment of benign prostatic hyperplasia.
1. A method of treating benign prostatic hyperplasia (BPH) in a subject, the method comprising administering to the subject anethole trithione (ATT) so as to treat the BPH.
2. The method of claim 1 , wherein the administering to the subject is performed following chronic prostatitis.
3. The method of claim 1 , wherein the ATT is administered in monotherapy.
4. The method of claim 1 , further comprising administering to the subject the ATT at a daily dose between 40 mg and 400 mg.
5. The method of claim 4 , comprising administering to the subject the ATT at a daily dose between 80 mg and 240 mg.
6. The method of claim 5 , comprising administering to the subject the ATT at a daily dose of 80 mg.
7. A method of decreasing prostatic androgenic signal associated with benign prostatic hyperplasia (BPH) in a subject, the method comprising administering to the subject anethole trithione (ATT) so as to treat the BPH.
8. The method of claim 7 , further comprising administering to the subject the ATT at a daily dose between 40 mg and 400 mg.
9. The method of claim 8 , comprising administering to the subject the ATT at a daily dose between 80 mg and 240 mg.
10. The method of claim 9 , comprising administering to the subject the ATT at a daily dose of 80 mg.
11. A method of inhibiting and/or decreasing prostatic inflammation associated with benign prostatic hyperplasia (BPH) in a subject, the method comprising administering to the subject anethole trithione (ATT) so as to treat the BPH.
12. The method of claim 11 , further comprising administering to the subject the ATT at a daily dose between 40 mg and 400 mg.
13. The method of claim 12 , comprising administering to the subject the ATT at a daily dose between 80 mg and 240 mg.
14. The method of claim 13 , comprising administering to the subject the ATT at a daily dose of 80 mg per administration.
15. A method of decreasing prostatic androgenic signal and prostatic inflammation associated with benign prostatic hyperplasia (BPH) in a subject, the method comprising administering to the subject anethole trithione (ATT) so as to treat the BPH.
16. The method of claim 15 , further comprising administering to the subject the ATT at a daily dose between 40 mg and 400 mg.
17. The method of claim 16 , comprising administering to the subject the ATT at a daily dose between 80 mg and 240 mg.
18. The method of claim 17 , comprising administering to the subject the ATT at a daily dose of 80 mg.